1. Introduction
===============

Coronary heart disease (CHD) is a complex chronic inflammatory process mediated by the innate and acquired immune systems and involves pro- and anti-inflammatory cytokines \[[@B1-ijms-15-23227]\]. Evidence indicates the interleukin 33/interleukin 1 receptor-like 1 (*IL-33/ST2*) axis participates in various fields of cardiovascular disease \[[@B2-ijms-15-23227],[@B3-ijms-15-23227],[@B4-ijms-15-23227],[@B5-ijms-15-23227],[@B6-ijms-15-23227],[@B7-ijms-15-23227]\]. IL-33 is a member of the interleukin-1 family of cytokines, and ST2, which consists of a transmembrane ligand (ST2L), a soluble component (sST2), and ST2V, is the receptor for IL-33 \[[@B8-ijms-15-23227]\]. IL-33 and ST2L form a heterodimeric receptor complex with IL-1R accessory protein (IL-1RAcP) \[[@B9-ijms-15-23227],[@B10-ijms-15-23227]\]. By interacting with ST2L, IL-33 prevents cardiomyocyte apoptosis and attenuates myocardial fibrosis and myocyte hypertrophy \[[@B4-ijms-15-23227]\]. *In vivo*, IL-33 significantly attenuates atherosclerotic cardiovascular disease in ApoE^−/−^ mice on a high-fat diet via the induction of IL-5 and oxidized low-density lipoprotein antibodies. The IL-33 decoy receptor, sST2, alters the atheroprotective activity of IL-33 \[[@B2-ijms-15-23227]\]. In contrast, other studies have reported that IL-33 promotes adhesion molecules and inflammatory activation in human endothelial cells and may, in such way, enhance the development of atherosclerotic lesions in the vessel wall \[[@B11-ijms-15-23227],[@B12-ijms-15-23227]\]. The mechanisms of these contradictory effects of IL-33 are not yet completely understood yet. Clinically, IL-33 serum levels were elevated in patients with heart failure and associated with coronary in-stent restenosis and mortality in patients with ST elevation myocardial infarction \[[@B13-ijms-15-23227],[@B14-ijms-15-23227],[@B15-ijms-15-23227],[@B16-ijms-15-23227]\]. Furthermore, sST2 has been demonstrated as a strong prognostic biomarker in patients with heart failure and myocardial infarction \[[@B3-ijms-15-23227],[@B5-ijms-15-23227],[@B17-ijms-15-23227],[@B18-ijms-15-23227],[@B19-ijms-15-23227]\].

Despite powerful biological and prognostic data describing the role of IL-33/ST2 signaling in the development of CHD, there is little information regarding the significance of *IL-33/ST2* genetic variants in CHD. Recently, Tsapaki *et al.* revealed that two polymorphisms in the distal promoter region of *ST2* were associated with susceptibility to severe CHD \[[@B20-ijms-15-23227]\]. In addition, polymorphisms in genes involved in the IL-33/ST2 pathway have been associated with several immune and inflammatory diseases \[[@B21-ijms-15-23227],[@B22-ijms-15-23227],[@B23-ijms-15-23227],[@B24-ijms-15-23227],[@B25-ijms-15-23227],[@B26-ijms-15-23227],[@B27-ijms-15-23227],[@B28-ijms-15-23227],[@B29-ijms-15-23227],[@B30-ijms-15-23227],[@B31-ijms-15-23227],[@B32-ijms-15-23227],[@B33-ijms-15-23227]\].

Therefore, considering the role of inflammation in CHD, we hypothesized that polymorphisms in *IL-33/ST2* might be associated with CHD risk. To test this hypothesis, we performed a genetic association analysis of *IL-33/ST2* and CHD risk in a case-control study of the Han Chinese population.

2. Results and Discussion
=========================

2.1. Characteristics of the Case and Control Subjects
-----------------------------------------------------

The general characteristics of the case-control study population are presented in [Table 1](#ijms-15-23227-t001){ref-type="table"}. Age and sex were similar for case and control subjects. Traditional CHD risk factors, such as body mass index (BMI) and fasting blood glucose (FBG), were significantly higher in CHD cases than in control subjects. CHD cases were more likely have a history of hypertension, diabetes mellitus (DM), and a family history of CHD. Total cholesterol (TC) levels were significantly lower in the cases than in the controls, possibly due to the use of cholesterol-lowering medications in this population.
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###### 

General characteristics of the study population.

  Variables                           Cases (*n* = 1146)    Controls (*n* = 1146)   *p* Value
  ----------------------------------- --------------------- ----------------------- -----------
  Sex, m/f (%)                        901/245 (78.6/21.4)   891/255 (77.7/22.3)     0.613
  Age, years                          60.5 ± 11.3           60.0 ± 10.3             0.23
  Blood pressure, mmHg                                                              
  Systolic                            133.6 ± 29.0          136.0 ± 25.3            0.034
  Diastolic                           82.0 ± 11.3           82.9 ± 15.2             0.11
  Body mass index, kg/m^2^            23.7 ± 3.1            24.4 ± 3.3              \<0.01
  Fasting glucose, mmol/L             5.6 ± 2.2             6.2 ± 3.0               \<0.01
  Total cholesterol, mmol/L           4.35 ± 1.10           4.68 ± 0.92             \<0.01
  Triglyceride, mmol/L                1.61 ± 1.30           1.67 ± 1.38             0.283
  Smoking, no/yes (%)                 686/460 (59.9/40.1)   774/369 (67.7/32.3)     \<0.01
  Alcohol drinking, no/yes (%)        776/365 (68.0/32.0)   822/317 (72.2/27.8)     \<0.01
  Past history                                                                      
  Hypertension, no/yes                784/361 (68.5/31.5)   351/790 (30.8/69.2)     \<0.01
  Diabetics, no/yes                   1080/65 (94.3/5.7)    824/314 (72.4/27.6)     \<0.01
  Family history of CHD, no/yes (%)   1133/10 (99.1/0.9)    947/158 (85.7/14.3)     \<0.01

Variables are presented as the mean ± SD or percentage. *p*-Values were calculated; using independent-sample *t*-tests or Chi-square tests.

2.2. Associations between Interleukin 33 (IL-33)/Interleukin 1 Receptor-Like 1 (ST2)/IL-1R Accessory Protein (IL-1RAcP) Variants and Coronary Heart Disease (CHD) Risk
----------------------------------------------------------------------------------------------------------------------------------------------------------------------

All the SNPs conformed to Hardy--Weinberg equilibrium (HWE) (*p* \> 0.001) except rs1157505, which significantly deviated from HWE in both control subjects and CHD cases (*p* \< 0.001). The minor allele frequency (MAF) for -27307T/A and -27614C/A were 0, and these alleles have not previously been found in the Chinese Han population according to the HapMap database. Thus, 25 SNPs were selected for further analysis. To analyze the associations between these SNPs and CHD risk, we compared differences in the genotype distribution of each polymorphism between case and control subjects and analyzed the genotypes as dominant/recessive models. As shown in [Table 2](#ijms-15-23227-t002){ref-type="table"}, homozygous rs4624606 variants (AA) had a significantly increased risk of CHD (OR = 1.85; 95% CI = 1.01--3.36; *p* = 0.045) compared to subjects with homozygous wild-type alleles (TT) after adjustment for conventional CHD risk factors, such as age, sex, smoking, drinking, BMI, triglyceride (TG), hypertension, DM, and family history of CHD. The SNP rs4624606 was also associated with a significantly increased risk of CHD in a recessive model (AA *vs.* (TT *+* TA): OR = 1.85; 95% CI = 1.02--3.35; *p* = 0.043, [Table 2](#ijms-15-23227-t002){ref-type="table"}). This study had greater than 90% power to detect the associations between rs4624606 and CHD risk \> 1.85 at a 0.05 significance level under both additive and recessive models. However, *p*-values for rs4624606 failed to reach significance after Bonferroni correction (*p* \> 0.002). There was no significant association between the remaining 24 SNPs and CHD risk in the Chinese population (*p* \> 0.05).

ijms-15-23227-t002_Table 2

###### 

Genotype frequencies of 25 SNPs and their association with coronary heart disease (CHD) risk in the Chinese population.

  SNPs          Case ^a^      Control ^a^   Heterozygote ^b^    Variant Homozygote ^b^   Dominant Model ^c^   Recessive Model ^d^                                                       
  ------------- ------------- ------------- ------------------- ------------------------ -------------------- --------------------- ------------------- ------- ----------------------- -----------
  *IL33*                                                                                                                                                                                
  rs1929992     353/538/217   369/527/210   1.04 (0.82--1.32)   0.733                    1.11 (0.83--1.49)    0.485                 1.06 (0.85--1.32)   0.594   1.08 (0.84--1.41)       0.542
  rs10975520    327/554/246   335/539/234   1.00 (0.79--1.27)   0.987                    1.08 (0.81--1.44)    0.618                 1.02 (0.82--1.28)   0.83    1.07 (0.84--1.38)       0.570
  rs11792633    361/552/222   363/530/211   1.01 (0.80--1.28)   0.912                    1.09 (0.81--1.45)    0.581                 1.03 (0.83--1.29)   0.762   1.08 (0.83--1.39)       0.571
  rs1624159     1010/94/3     1020/91/6     0.88 (0.61--1.28)   0.513                    2.83 (0.58--13.9)    0.199                 0.93 (0.65--1.35)   0.709   2.86 (0.58--14.04)      0.195
  *ST2*                                                                                                                                                                                 
  rs3755278     974/86/3      1045/89/4     1.02 (0.70--1.49)   0.928                    3.44 (0.53--22.19)   0.193                 1.06 (0.73--1.54)   0.743   3.44 (0.53--22.16)      0.194
  rs3821204     457/512/157   452/522/134   0.94 (0.76--1.18)   0.612                    1.26 (0.90--1.75)    0.178                 1.00 (0.81--1.24)   0.972   1.30 (0.95--1.77)       0.102
  rs13431828    925/194/15    932/166/10    1.16 (0.88--1.54)   0.284                    0.91 (0.35--2.38)    0.843                 1.15 (0.87--1.50)   0.326   0.89 (0.34--2.32)       0.805
  rs10206753    839/272/26    832/252/24    1.07 (0.84--1.37)   0.562                    0.97 (0.49--1.93)    0.939                 1.06 (0.84--1.34)   0.598   0.96 (0.48--1.89)       0.898
  rs1041973     845/248/41    844/234/30    1.00 (0.78--1.29)   0.977                    1.41 (0.79--2.49)    0.243                 1.05 (0.83--1.33)   0.681   1.40 (0.80--2.48)       0.242
  rs12999364    409/536/185   407/527/174   0.99 (0.79--1.24)   0.908                    1.13 (0.83--1.55)    0.436                 1.02 (0.82--1.26)   0.854   1.14 (0.86--1.51)       0.363
  rs6543116     337/571/216   326/537/245   1.02 (0.81--1.30)   0.845                    0.82 (0.61--1.10)    0.189                 0.96 (0.77--1.21)   0.735   0.81 (0.62--1.04)       0.101
  rs951774      660/413/58    630/408/70    0.91 (0.73--1.13)   0.377                    0.91 (0.57--1.45)    0.683                 0.91 (0.74--1.12)   0.358   0.94 (0.60--1.49)       0.8
  rs10515922    843/263/26    833/247/28    1.00 (0.78--1.27)   0.976                    1.13 (0.55--2.29)    0.745                 1.01 (0.79--1.28)   0.955   1.13 (0.55--2.29)       0.742
  rs13006559    1063/77/2     1046/59/3     1.24 (0.80--1.94)   0.34                     1.37 (0.12--15.25)   0.798                 1.25 (0.80--1.93)   0.326   1.36 (0.12--15.10)      0.804
  *IL--1RAcP*                                                                                                                                                                           
  rs1015704     725/359/46    686/381/41    0.89 (0.71--1.11)   0.295                    1.02 (0.59--1.78)    0.935                 0.90 (0.73--1.12)   0.34    1.07 (0.62--1.84)       0.819
  rs9817203     515/493/122   506/489/113   1.05 (0.84--1.30)   0.685                    1.24 (0.87--1.77)    0.228                 1.08 (0.88--1.33)   0.461   1.22 (0.87--1.70)       0.255
  rs1559018     300/549/279   276/569/262   0.97 (0.76--1.25)   0.825                    1.14 (0.85--1.53)    0.378                 1.02 (0.81--1.30)   0.846   1.16 (0.91--1.48)       0.223
  rs3773986     861/245/19    844/250/14    1.01 (0.79--1.29)   0.936                    1.23 (0.52--2.91)    0.644                 1.02 (0.80--1.30)   0.86    1.22 (0.52--2.90)       0.647
  rs6765375     736/350/45    699/375/34    0.89 (0.71--1.11)   0.301                    1.18 (0.66--2.11)    0.576                 0.91 (0.74--1.13)   0.408   1.23 (0.69--2.18)       0.486
  rs4624606     734/338/46    731/351/26    0.99 (0.79--1.25)   0.962                    1.85 (1.01--3.36)    0.045                 1.05 (0.85--1.31)   0.636   **1.85 (1.02--3.35)**   **0.043**
  rs16865597    877/204/12    854/223/17    1.02 (0.78--1.32)   0.892                    1.19 (0.45--3.12)    0.728                 1.03 (0.79--1.33)   0.837   1.18 (0.45--3.11)       0.733
  rs4687150     559/434/105   543/433/110   0.92 (0.74--1.15)   0.459                    0.90 (0.62--1.30)    0.58                  0.92 (0.74--1.13)   0.412   0.94 (0.66--1.33)       0.712
  rs3773958     380/548/200   368/534/206   0.97 (0.77--1.22)   0.779                    0.95 (0.70--1.28)    0.729                 0.96 (0.77--1.20)   0.728   0.97 (0.74--1.26)       0.806
  rs3773981     695/330/57    726/336/42    0.94 (0.75--1.18)   0.59                     1.09 (0.65--1.80)    0.751                 0.96 (0.77--1.19)   0.692   1.11 (0.67--1.83)       0.689
  rs6444435     638/340/65    691/363/51    0.97 (0.77--1.22)   0.797                    1.39 (0.87--2.23)    0.168                 1.02 (0.82--1.27)   0.843   1.41 (0.88--2.24)       0.150

^a^ Wild-type homozygote/heterozygote/variant homozygote; ^b^ The reference group comprised subjects homozygous for the wild-type allele; ^c^ Dominant model (wild-type homozygote *vs.* heterozygote + variant homozygote); ^d^ Recessive model (wild-type homozygote + heterozygote *vs.* variant homozygote); ^e^ Data were calculated by unconditional logistic regression, adjusted for age, sex, smoking, drinking, BMI, TG, hypertension, DM, and family history of CHD. Numbers in bold mean the SNP rs4624606 was also associated with a significantly increased risk of CHD in a recessive model (AA *vs.* (TT *+* TA): OR = 1.85; 95% CI = 1.02--3.35; *p* = 0.043, [Table 2](#ijms-15-23227-t002){ref-type="table"}).

2.3. Association Analyses for Stratified Traditional Risk Factors
-----------------------------------------------------------------

To evaluate whether traditional risk factors influenced the effects of genetic variants on CHD risk, we conducted stratification analysis for rs4624606 by sex, smoking, drinking, BMI, hypertension, and diabetes and examined the interactions between this SNP and traditional risk factors for CHD risk. As shown in [Table 3](#ijms-15-23227-t003){ref-type="table"}, rs4624606 was associated with higher risk in hypertensive subjects (AA *vs.* TT: OR = 2.77, 95% CI = 1.01--7.57; AA *vs.* (TT *+* TA): OR = 2.91, 95% CI = 1.07--7.93). However, no significant interactions were observed between rs4624606 and sex, smoking, drinking, BMI, hypertension, or diabetes (all *p* \> 0.05).
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###### 

Stratification analysis for the association between rs4624606 and the risk of CHD.

  rs4624606 OR (95% CI) ^a^                                                                                                     
  --------------------------- ------ ------------------- --------------------------- ------- ------ --------------------------- -------
  Sex                                                                                                                           
  Male                        1.00   0.95 (0.74--1.22)   1.70 (0.89--3.23)           0.515   1.00   1.72 (0.91--3.27)           0.826
  Female                      1.00   1.24 (0.72--2.12)   1.37 (0.22--8.69)                   1.00   1.26 (0.20--7.93)           
  Smoke status                                                                                                                  
  Smokers                     1.00   0.98 (0.67--1.45)   1.68 (0.58--4.88)           0.820   1.00   1.69 (0.59--4.87)           0.951
  Nonsmokers                  1.00   0.95 (0.72--1.26)   1.82 (0.87--3.80)                   1.00   1.85 (0.89--3.84)           
  Drink                                                                                                                         
  Drinkers                    1.00   0.92 (0.60--1.39)   1.99 (0.61--6.43)           0.974   1.00   1.74 (0.86--3.53)           0.793
  Nondrinkers                 1.00   1.00 (0.76--1.30)   1.74 (0.85--3.55)                   1.00   2.04 (0.64--6.56)           
  BMI, kg/m^2^                                                                                                                  
  \< 25                       1.00   1.08 (0.82--1.43)   1.55 (0.70--3.47)           0.204   1.00   1.52 (0.68--3.38)           0.365
  ≥ 25                        1.00   0.85 (0.58--1.24)   2.24 (0.88--5.75)                   1.00   2.33 (0.92--5.91)           
  Hypertension                                                                                                                  
  No                          1.00   1.22 (0.89--1.68)   1.32 (0.57--3.05)           0.491   1.00   1.24 (0.54--2.84)           0.246
  Yes                         1.00   0.85 (0.62--1.17)   **2.77 (1.01--7.57) ^c^**           1.00   **2.91 (1.07--7.93) ^c^**   
  Diabetes                                                                                                                      
  No                          1.00   1.02 (0.80--1.29)   1.85 (0.99--3.44)           0.626   1.00   1.84 (0.99--3.40)           0.941
  Yes                         1.00   0.87 (0.42--1.79)   1.72 (0.17--17.27)                  1.00   1.78 (0.18--17.72)          

^a^ ORs were obtained from an unconditional logistic regression model with adjustment for age, sex, smoking, drinking, BMI, TG, hypertension, DM, and family history of CHD. For each stratified analysis, adjustments were made for all other variables excluding the stratified variable; ^b^ *p*-Values of interactions were calculated by unconditional logistic regression; ^c^ *p* \< 0.05.

3. Discussion
=============

In this case-control study, we investigated the associations of 28 polymorphisms in IL-33/ST2 signaling pathway genes with the risk of CHD. Our results showed that subjects with the rs4624606 AA genotype in the *IL-1RAcP* gene had an increased risk of CHD. Especially among hypertensive subjects, the genotype AA was strongly associated with a higher risk of CHD. It is possible that hypertension may exacerbate the influence of genetic factors. No variants in *IL-33* or *ST2* were associated with CHD risk. Moreover, no interactions were observed between these SNPs and CHD traditional risk factors.

Numerous *in vitro* and *in vivo* model studies have found that activation of the IL-33/ST2 signaling pathway can significantly attenuate the severity of CHD \[[@B4-ijms-15-23227]\]. IL-33 appears to provide anti-atherosclerotic benefits in CHD. Furthermore, the sST2 isoform acts as a decoy receptor to reduce IL-33 signaling through the ST2L receptor and is a significant predictor of mortality in patients with several cardiovascular disorders \[[@B6-ijms-15-23227]\]. To further explore the role of the *IL-33* gene in the pathogenesis of CHD, we tested the association between *IL-33* polymorphisms and CHD; however, no significant associations were found, nor were there significant interactions between these SNPs and traditional CHD risk factors.

The *ST2* gene is located in chromosome 2q12 and contains 11 exons, a proximal promoter, and a distal promoter \[[@B24-ijms-15-23227]\]. Many researchers have reported that rs6543116 (-26999G/A) in the distal promoter region of *ST2* is associated with increased risk for atopic dermatitis and asthma \[[@B32-ijms-15-23227],[@B34-ijms-15-23227]\]. Recently, Tsapaki *et al.* reported that -27307T/A and -27614C/A polymorphisms in the distal promoter region of *ST2* influence susceptibility to severe CHD \[[@B20-ijms-15-23227]\]. Based on these results, we hypothesized that SNPs in the distal promoter region of *ST2* might be associated with CHD risk. In this study, we replicated these SNPs (rs6543116, -27307T/A, -27614C/A) and examined another three SNPs (rs951774, rs10515922, and 13006559) in the distal promoter region, which were selected by extending 30 kb into the 5\' end of *ST2*. We also analyzed the tagSNPs in the *ST2* gene to explore the genetic role of *ST2* in the pathogenesis of CHD. However, we failed to show an association between these SNPs and CHD. One possibility for this discrepancy may be due to ethnic and phenotypic differences and disparate environmental effects between countries.

IL-1RAcP is a member of the *IL-33/ST2* axis receptor complex and has been reported to play an important role in CHD \[[@B9-ijms-15-23227]\]. Soluble IL-1RAcP interacts with the sST2-IL-33 complex to increase inhibition of IL-33 signaling. The *IL-1RAcP* gene is located on chromosome 3q28. Genetic variants in *IL-1RAcP* have been associated with prostate cancer, Kawasaki disease, and persistent hepatitis B virus \[[@B23-ijms-15-23227],[@B30-ijms-15-23227],[@B33-ijms-15-23227]\]; however, the role of *IL-1RAcP* polymorphisms in CHD has never been investigated. In this study, we selected 11 tagSNPs and found that rs4624606 was associated with increased risk of CHD. Ramkumar *et al.* also reported that rs4624606 was associated with higher amniotic fluidIL-1β concentrations \[[@B26-ijms-15-23227]\]. The SNP rs4624606 is located in the intron of *IL-1RAcP*. However, no functional studies have been performed to determine the characteristics of this SNP. Further research is required to understand the functions of variants associated with CHD.

Our study has several limitations. First, like other case-control studies, a possible selection bias (inclusion of surviving CHD patients) may exist. Second, not all controls had coronary angiography, introducing the possibility of false-negative cases. However, our controls had normal electrocardiography (ECG), no clinical symptoms, and no history of CHD before enrollment; additionally, false negatives are likely to be rare.

4. Experimental Section
=======================

4.1. Study Population
---------------------

The sample population included 1146 patients and 1146 age- and sex-frequency-matched controls. CHD patients were recruited from three hospitals (Union Hospital, Tongji Hospital, and Wugang Hospital) in Wuhan, China \[[@B35-ijms-15-23227],[@B36-ijms-15-23227]\]. CHD was diagnosed as angiographically demonstrated stenoses (≥50%) in a major or main branch of the coronary artery \[[@B37-ijms-15-23227]\]. The control subjects, residing in the same communities as the patients, were determined to be free of CHD and peripheral atherosclerotic arterial disease by medical history, clinical examinations, and ECG. All subjects completed an Inter-Heart questionnaire and were interviewed about their demographic data, medical history, history of disease, family history of cardiovascular disease, and lifestyle habits (including smoking and alcohol consumption) by trained interviewers. The study was approved by the Ethics Committee of Tongji Medical College (project identification code: S073, 21 February 2011), and all participants provided written informed consent.

4.2. Selection of Polymorphisms
-------------------------------

TagSNPs were selected based on the HapMap phase I & II database (<http://www.hapmap.org>, CHB and JPT as the reference set). According to the criteria of *r*^2^ ≥ 0.8 and minor allele frequency (MAF) ≥ 0.05, we extended 2000 bp into the 5\' and 3\' ends of *IL-33* and *IL-1RAcP*. To cover the distal promoter region of *ST2*, we extended 30 kb into the 5\' and 2000 bp into the 3\' end of *ST2*. Thus, we selected 18 tagSNPs in the three genes. We selected another 10 SNPs from previous reports in CHD (-27307T/A, -27614C/A) and other diseases, including Alzheimer's disease, asthma, and atopic dermatitis \[[@B20-ijms-15-23227],[@B21-ijms-15-23227],[@B32-ijms-15-23227],[@B38-ijms-15-23227]\]. In total, we selected and genotyped 28 SNPs ([Table 4](#ijms-15-23227-t004){ref-type="table"}).
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###### 

SNP locations and allele frequencies.

  SNP          Gene         Location              Genotype   MAF \*   HWE *p* \*
  ------------ ------------ --------------------- ---------- -------- ------------
  rs1929992    *IL33*       Intron                A/G        0.489    0.655
  rs10975520   *IL33*       Intron                G/C        0.488    1
  rs11792633   *IL33*       Intron                T/C        0.433    --
  rs1157505    *IL33*       Intron                G/C        0.225    --
  rs1624159    *IL33*       Between genes         A/G        0.06     0.02
  rs3755278    *ST2*        intron                A/G        0.067    1
  rs3821204    *ST2*        3\'-Flanking region   C/G        0.358    0.403
  rs13431828   *ST2*        5\'-Flanking region   T/C        0.089    1
  rs10206753   *ST2*        Exon                  C/T        0.133    1
  rs1041973    *ST2*        Exon                  A/C        0.156    0.527
  rs12999364   *ST2*        Between genes         T/C        0.45     --
  rs6543116    *ST2*        Distal promoter       A/G        0.367    --
  rs951774     *ST2*        Distal promoter       A/C        0.233    0.251
  rs10515922   *ST2*        Distal promoter       C/T        0.151    1
  rs13006559   *ST2*        Distal promoter       T/C        0.07     1
  -27307T/A    *ST2*        Distal promoter       T/A        --       --
  -27614C/A    *ST2*        Distal promoter       C/A        --       --
  rs1015704    *IL-1RAcP*   intron                G/A        0.222    0.294
  rs9817203    *IL-1RAcP*   intron                T/C        0.395    0.439
  rs1559018    *IL-1RAcP*   intron                G/A        0.488    0.479
  rs3773986    *IL-1RAcP*   intron                T/C        0.067    1
  rs6765375    *IL-1RAcP*   intron                C/A        0.233    1
  rs4624606    *IL-1RAcP*   intron                A/T        0.213    0.294
  rs16865597   *IL-1RAcP*   intron                C/T        0.159    0.273
  rs4687150    *IL-1RAcP*   intron                T/C        0.341    0.403
  rs3773958    *IL-1RAcP*   intron                G/T        0.419    0.752
  rs3773981    *IL-1RAcP*   intron                C/A        0.182    0.584
  rs6444435    *IL-1RAcP*   intron                A/G        0.251    0.233

**\*** Data from the NCBI; -- Data were not found in <http://www.ncbi.nlm.nih.gov/snp/>.

4.3. DNA Isolation and Genotyping
---------------------------------

Fasting venous blood was collected from the peripheral vein, and genomic DNA was extracted with a Puregene kit (Gentra Systems Inc., Minneapolis, MN, USA). Twenty-five SNPs were genotyped using the Sequenom MassArray system (Sequenom Inc., San Diego, CA, USA). The remaining rs3755278, rs6444435, and rs1157505 SNPs were genotyped by TaqMan SNP allelic discrimination (Applied Biosystems, Foster City, CA, USA). TaqMan data collection and analysis were performed with SDS 2.2.1. Thus, 28 SNPs were successfully genotyped with a successful call rate of greater than 95%, with the exception of rs6444435, for which the call rate was 93.7%.

4.4. Biological Variable Determination
--------------------------------------

FBG, TC, and TG were assayed by standard laboratory procedures in the clinical laboratory department at Union Hospital.

4.5. Statistical Analysis
-------------------------

Continuous variables are expressed as means ± standard deviation (SD). The normal distribution of data was verified by the Kolmogorov--Smirnov normality test. Continuous data with a normal distribution were compared by Student's *t-*test, and those with unequal variance or without a normal distribution were analyzed by Mann--Whitney rank-sum tests. Chi-square tests were used to compare categorical variables and the HWE of the polymorphisms. Unconditional logistic regression analysis was used to estimate the associations between SNPs and CHD risk after adjustment for age, sex, smoking, drinking, body mass index (BMI), TG, hypertension, DM, and family history of CHD by odds ratios (ORs) and 95% confidence intervals (CIs). The interactions of covariates with SNP genotypes were tested using the Wald test in unconditional logistic regression models. The significance of multiplicative interactions between SNPs and covariates was determined by the likelihood ratio test using the logistic regression model. Power calculations were performed using the QUANTO software program (Version 1.2.3) \[[@B39-ijms-15-23227]\]. All other statistical analyses were carried out with the statistical analysis software package SPSS 12.0 (SPSS Inc., Chicago, IL, USA). Differences or associations with *p*-values of less than 0.05 were considered significant.

5. Conclusions
==============

In conclusion, we found that the SNP rs4624606 within the *IL-1RAcP* locus was nominally associated with CHD susceptibility. Further studies in other independent populations with large sample sizes are required to validate these findings.
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